Mynosys ZEPTO medical device receives CE Mark

Share Article

Mynosys Cellular Devices announces CE mark approval for the ZEPTO™ device for performing anterior lens capsulotomy during cataract surgery. With CE mark approval, the ZEPTO device offers ophthalmic physicians in Europe the most advanced method for performing an automated capsulotomy during cataract surgery.

Mynosys Cellular Devices, Inc., an ophthalmic medical device company, today announced the company has received CE mark approval for the ZEPTO capsulotomy device. ZEPTO is a disposable automated capsulotomy device that provides surgeons with round, accurately sized, and well-centered capsulotomies without interrupting surgical routine and patient flow. The product uses a highly focused multipulse low-energy discharge to produce a complete, round anterior capsulotomy simultaneously along 360 degrees within milliseconds. The ZEPTO handpiece, with its soft collapsible capsulotomy tip, is an alternative to manual capsulorhexis and allows capsulotomy alignment with the patient’s visual axis for optimized IOL placement and effective lens positioning. In use, the ZEPTO handpiece is connected to a small power console located away from the sterile field.

ZEPTO is targeted at ophthalmic surgeons who perform cataract surgery. An in-depth market development analysis was conducted by an independent third party to evaluate ZEPTO’s projected rate of adoption, barriers, market penetration, and sizing. Detailed disease and patient segmentation, treatment landscape, and health care and government data were combined with validated statistical engines and behavioral change theory. The analysis revealed ZEPTO to be a compelling product with few barriers to adoption.

“The most compelling patient segment with comorbidities represents 25% of the cataract surgical population and is an ideal target segment to support rapid ZEPTO penetration to access the early majority. ZEPTO’s ease of use and superior performance will accelerate broad adoption to become the standard of care with minimal marketing and selling elements,” said John N. Hendrick, President and CEO of Mynosys.

Research was supported by the National Eye Institute of the National Institutes of Health under Award Number R44EY021023. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Hendrick
Visit website